- Home
- ITRM vs BILI Comparison
ITRM vs BILI Comparison
Compare ITRM & BILI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- BILI
- Stock Information
- Founded
- ITRM 2015
- BILI 2009
- Country
- ITRM Ireland
- BILI China
- Employees
- ITRM N/A
- BILI N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- BILI EDP Services
- Sector
- ITRM Health Care
- BILI Technology
- Exchange
- ITRM Nasdaq
- BILI Nasdaq
- Market Cap
- ITRM 37.7M
- BILI N/A
- IPO Year
- ITRM 2018
- BILI 2018
- Fundamental
- Price
- ITRM $1.08
- BILI $16.21
- Analyst Decision
- ITRM Strong Buy
- BILI Strong Buy
- Analyst Count
- ITRM 1
- BILI 9
- Target Price
- ITRM $5.00
- BILI $20.59
- AVG Volume (30 Days)
- ITRM 300.3K
- BILI 5.6M
- Earning Date
- ITRM 05-12-2025
- BILI 05-22-2025
- Dividend Yield
- ITRM N/A
- BILI N/A
- EPS Growth
- ITRM N/A
- BILI N/A
- EPS
- ITRM N/A
- BILI N/A
- Revenue
- ITRM N/A
- BILI $3,676,004,571.00
- Revenue This Year
- ITRM N/A
- BILI $15.36
- Revenue Next Year
- ITRM $150.10
- BILI $8.96
- P/E Ratio
- ITRM N/A
- BILI N/A
- Revenue Growth
- ITRM N/A
- BILI 19.10
- 52 Week Low
- ITRM $0.81
- BILI $10.84
- 52 Week High
- ITRM $3.02
- BILI $31.77
- Technical
- Relative Strength Index (RSI)
- ITRM 32.84
- BILI 38.15
- Support Level
- ITRM $1.05
- BILI $15.87
- Resistance Level
- ITRM $1.16
- BILI $17.50
- Average True Range (ATR)
- ITRM 0.08
- BILI 0.93
- MACD
- ITRM -0.00
- BILI -0.09
- Stochastic Oscillator
- ITRM 13.04
- BILI 35.05
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.